BCTX BRIACELL THERAPEUTICS CORP Investments/Divestments 8-K Filing 2023 - Patent Issuance and FDA Guidance BriaCell Therapeutics Corp. announced the issuance of a US patent and an Australian patent for their personalized off-the-shelf cell-based immunotherapy for cancer, as well as FDA guidance for the development of their clinical-grade cell lines and the addition of new sites for their Phase II study.Get access to all SEC 8-K filings of the BRIACELL THERAPEUTICS CORP